1. Home
  2. MGX vs BDL Comparison

MGX vs BDL Comparison

Compare MGX & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGX
  • BDL
  • Stock Information
  • Founded
  • MGX 2018
  • BDL 1959
  • Country
  • MGX United States
  • BDL United States
  • Employees
  • MGX N/A
  • BDL N/A
  • Industry
  • MGX
  • BDL Restaurants
  • Sector
  • MGX
  • BDL Consumer Discretionary
  • Exchange
  • MGX NYSE
  • BDL Nasdaq
  • Market Cap
  • MGX 62.1M
  • BDL 60.8M
  • IPO Year
  • MGX 2024
  • BDL N/A
  • Fundamental
  • Price
  • MGX $2.17
  • BDL $33.25
  • Analyst Decision
  • MGX Strong Buy
  • BDL
  • Analyst Count
  • MGX 4
  • BDL 0
  • Target Price
  • MGX $13.00
  • BDL N/A
  • AVG Volume (30 Days)
  • MGX 912.4K
  • BDL 1.9K
  • Earning Date
  • MGX 08-13-2025
  • BDL 08-12-2025
  • Dividend Yield
  • MGX N/A
  • BDL 1.48%
  • EPS Growth
  • MGX N/A
  • BDL 14.76
  • EPS
  • MGX N/A
  • BDL 2.18
  • Revenue
  • MGX $45,263,000.00
  • BDL $198,785,000.00
  • Revenue This Year
  • MGX N/A
  • BDL N/A
  • Revenue Next Year
  • MGX $11.75
  • BDL N/A
  • P/E Ratio
  • MGX N/A
  • BDL $15.26
  • Revenue Growth
  • MGX N/A
  • BDL 9.31
  • 52 Week Low
  • MGX $1.23
  • BDL $22.61
  • 52 Week High
  • MGX $5.50
  • BDL $35.98
  • Technical
  • Relative Strength Index (RSI)
  • MGX 71.83
  • BDL 60.35
  • Support Level
  • MGX $1.45
  • BDL $30.11
  • Resistance Level
  • MGX $2.47
  • BDL $34.70
  • Average True Range (ATR)
  • MGX 0.16
  • BDL 0.85
  • MACD
  • MGX 0.09
  • BDL 0.06
  • Stochastic Oscillator
  • MGX 75.47
  • BDL 68.77

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

About BDL Flanigan's Enterprises Inc.

Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.

Share on Social Networks: